| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/50-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | PSMB8; LMP7; PSMB5i; RING10; Y2; Proteasome subunit beta type-8; Low molecular mass protein 7; Macropain subunit C13; Multicatalytic endopeptidase complex subunit C13; Proteasome component C13; Proteasome subunit beta-5i; Really interesting |
| Entrez GeneID | 5696 |
| WB Predicted band size | Calculated MW: 30 kDa; Observed MW: 23 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human Proteasome 20S LMP7 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于Proteasome beta 8(PSMB8/LMP7)抗体的3篇参考文献，按文献名称、作者和摘要内容概括整理：
---
1. **文献名称**: *"Immunoproteasome subunit LMP7 deficiency improves Alzheimer’s disease-like pathology in mice"*
**作者**: Chen et al.
**摘要内容**: 研究利用PSMB8/LMP7特异性抗体分析免疫蛋白酶体亚基在阿尔茨海默病模型小鼠中的表达，发现LMP7缺失可减少淀粉样斑块沉积，提示其作为治疗靶点的潜力。
---
2. **文献名称**: *"Targeting the immunoproteasome in autoimmune diabetes"*
**作者**: Basler et al.
**摘要内容**: 通过Western blot和免疫组化(使用抗PSMB8抗体)，证明抑制免疫蛋白酶体活性(包括LMP7)可延缓1型糖尿病进展，为自身免疫疾病提供新策略。
---
3. **文献名称**: *"A novel monoclonal antibody specific for PSMB8 reveals its role in cancer cell proliferation"*
**作者**: Yamamoto et al.
**摘要内容**: 报道一种高特异性抗PSMB8单克隆抗体的开发，验证其在流式细胞术和免疫荧光中的应用，并发现PSMB8高表达与癌细胞增殖和化疗耐药性相关。
---
4. **文献名称**: *"Immunoproteasome-specific inhibitors limit MHC class I antigen presentation and reduce tissue inflammation"*
**作者**: Muchamuel et al.
**摘要内容**: 研究通过抗PSMB8抗体检测免疫蛋白酶体活性，发现特异性抑制剂可降低炎症性疾病模型中的促炎细胞因子水平，支持免疫蛋白酶体靶向治疗炎症性疾病。
---
**说明**：上述文献为示例，实际引用时需核对具体数据库(如PubMed)或抗体厂商(如Abcam、CST)的产品引用文献，确保准确性。
Proteasome beta 8 (PSMB8), also known as β5i or LMP7. is a catalytic subunit of the immunoproteasome, a specialized form of the 20S proteasome. The immunoproteasome is primarily expressed in immune cells and is induced by pro-inflammatory cytokines like interferon-gamma (IFN-γ). Unlike the constitutive proteasome, the immunoproteasome optimizes antigen processing for major histocompatibility complex class I (MHC-I) presentation, generating peptides that are more suitable for immune recognition. PSMB8 plays a critical role in this process by cleaving peptide substrates after hydrophobic or basic residues.
Antibodies targeting PSMB8 are essential tools for studying immunoproteasome function and regulation. They are widely used in techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to detect PSMB8 expression in cells and tissues. These antibodies help elucidate its involvement in autoimmune diseases (e.g., lupus, rheumatoid arthritis), neurodegenerative disorders, and cancers, where immunoproteasome activity is often dysregulated. Additionally, PSMB8 mutations are linked to autoinflammatory syndromes like chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome.
Research using PSMB8 antibodies also explores therapeutic interventions, such as immunoproteasome inhibitors, which are being investigated for modulating immune responses in inflammatory diseases and enhancing cancer immunotherapy efficacy. The specificity and reliability of these antibodies are crucial for advancing our understanding of proteasome biology and its clinical implications.
×
